NEWS
Tulathromycin A
  • Approved Drug Name
    Tulathromycin A
  • CAS NO.
    217500-96-4
  • Quality Standard
    USP, EP, JP
  • Packaging
    10G/Bag, 100G/Bag, 1000G/Bag
  • Storage Condition
    Shading,Sealing,Store at room temperature
  • Certification
    Ongoing registration

Tulathromycin A(casno.217500-96-4) is a macrolide antibiotic used to treat bovine respiratory disease (BRD) in cattle and swine respiratory disease in pigs. It is marketed by Pfizer Inc. under the tradename Draxxin.
Tulathromycin A(casno.217500-96-4) is supplied as a solution for injection containing 100 mg of the drug.
Tulathromycin A(casno.217500-96-4) is a macrolide antibiotic that inhibits bacterial protein synthesis (IC50 = 0.26 μM) by targeting the 50S ribosomal subunit, blocking the progression of nascent polypeptide chains. Tulathromycin A(casno.217500-96-4) is effective against M.
haemolytica and P. multocida (MICs = 2 and 0.5 μg/ml, respectively), which cause respiratory tract infections in cattle and swine.
Tulathromycin A(casno.217500-96-4) Chemical Properties, Usage, Production:
Tulathromycin A(casno.217500-96-4) Chemical Properties:
White Solid
Tulathromycin A(casno.217500-96-4) Usage:
Tulathromycin A(casno.217500-96-4) is a semi-synthetic erythromycin belonging to the ring expanded aza–erythromycins. Ring expansion improvedsthe acid lability of the parent erythromycins. Tulathromycin A(casno.217500-96-4) is regarded as the first of the triamilides, having a third amino (propylaminomethylene) group on a sugar to improve absorption. This modification provides a mixture of the two tulathromycin isomers (90:10) present in the commercial animal health product.
Tulathromycin A(casno.217500-96-4) is a semi-synthetic erythromycin belonging to the ring expanded aza–erythromycins. Ring expansion improves the acid lability compared with the parent erythromycins. Tulathromycin A(casno.217500-96-4) is regarded as the first of the triamilides, having a third amino (propylaminomethylene) group on a sugar to improve absorption. This modification provides a mixture of the two tulathromycin isomers (90:10) present in the commercial animal health product.
Triamilide antibiotic for treatment of bovine and porcine respiratory disease. Exists as an equilibrium mixture of two isomeric forms, Tulathromycin A(casno.217500-96-4) (90%) and B (10%). Antibacterial.
keywords
Tulathromycin A Quality
Tulathromycin A Manufacturers
Tulathromycin A Suppliers
Tulathromycin A FDA
Tulathromycin A USP.EP
Tulathromycin A GMP
Tulathromycin A price
Tulathromycin A samples
Tulathromycin A(casno.217500-96-4) Appearance: White Solid
Tulathromycin A(casno.217500-96-4) Melting Point: 186-188℃
Tulathromycin A(casno.217500-96-4) Mol. Weight: 806.08
Tulathromycin A(casno.217500-96-4) Solubility: DMSO (Slightly), Methanol (Slightly)
Tulathromycin A(casno.217500-96-4) is a macrolide antibiotic. Antibiotics are a type of antimicrobial used in the treatment and prevention of bacterial infection. Two highly pathogenic strains of M. bovis were incubated into 145 calves. Four days later, calves with clinical BRD were treated subcutaneously with tulathromycin or saline (2.5 mg/kg). BRD-related withdrawals, peak rectal temperatures, and lung lesion scores were significantly lower for tulathromycin-treated calves. In the treatment of cattle at high risk of developing bovine respiratory disease, the cure rate treated with tulathromycin (78%) and tilmicosin (65%) was significantly higher than that treated with saline (23.8%). The cure rate treated with tulathromycin (78.4%) was also significantly higher than tilmicosin (64.9%).
The lowest tulathromycin concentrations inhibiting the 90% growth of isolates (MIC90) were 2 μg/ml for Mannheimia (Pasteurella) haemolytica, 1 μg/ml for Pasteurella multocida (bovine), and 2 μg/ml for Pasteurella multocida (porcine) and ranged from 0.5-4 μg/ml for Histophilus somni and from 4-16 μg/ml for Actinobacillus pleuropneumoniae. Tulathromycin has been approved for use in the treatment and prevention of swine and bovine respiratory disease.